Ghent University Academic Bibliography

Advanced

The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.

C Verslype, S Carton, I Borbath, T Delaunoit, P Demetter, G Demolin, A Hendlisz, Piet Pattyn UGent, S Pauwels, Marc Peeters UGent, et al. (2009) ACTA GASTRO-ENTEROLOGICA BELGICA. 72(1). p.54-58
abstract
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced by the production of hormones and peptides. The antiproliferative effects of SSAs and especially tumour shrinkage are less obvious in patients with GEP NETS than in those with acromegaly. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SSAs in selected patients. Those patients with a progressive, non-functional GEP NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SSAs. The exploration of the mechanisms of this effect are unclear and hampered by the lack of suitable preclinical models. The better understanding of the tumour biology of GEP NETS, together with the development of new SSAs with better affinity on all somatostatin receptors, represent an unmet medical need.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
somatostatin analogs, neuroendocrine tumors, antiproliferative effect, MALIGNANT CARCINOID-SYNDROME, CELL-LINE, OCTREOTIDE ACETATE, IN-VITRO, LANREOTIDE, EFFICACY, PROLIFERATION, GLUCAGONOMA, INHIBITION, MANAGEMENT
journal title
ACTA GASTRO-ENTEROLOGICA BELGICA
Acta Gastro-Enterol. Belg.
volume
72
issue
1
pages
54 - 58
Web of Science type
Review
Web of Science id
000265194500011
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
1.01 (2009)
JCR rank
54/64 (2009)
JCR quartile
4 (2009)
ISSN
0001-5644
language
English
UGent publication?
yes
classification
A1
id
687674
handle
http://hdl.handle.net/1854/LU-687674
date created
2009-06-10 11:41:22
date last changed
2016-12-19 15:42:37
@article{687674,
  abstract     = {Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced by the production of hormones and peptides. The antiproliferative effects of SSAs and especially tumour shrinkage are less obvious in patients with GEP NETS than in those with acromegaly. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SSAs in selected patients. Those patients with a progressive, non-functional GEP NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SSAs. The exploration of the mechanisms of this effect are unclear and hampered by the lack of suitable preclinical models.
The better understanding of the tumour biology of GEP NETS, together with the development of new SSAs with better affinity on all somatostatin receptors, represent an unmet medical need.},
  author       = {Verslype, C and Carton, S and Borbath, I and Delaunoit, T and Demetter, P and Demolin, G and Hendlisz, A and Pattyn, Piet and Pauwels, S and Peeters, Marc and Roeyen, G and Van Hootegem, P and Van Laethem, JL and Van Cutsem, E},
  issn         = {0001-5644},
  journal      = {ACTA GASTRO-ENTEROLOGICA BELGICA},
  keyword      = {somatostatin analogs,neuroendocrine tumors,antiproliferative effect,MALIGNANT CARCINOID-SYNDROME,CELL-LINE,OCTREOTIDE ACETATE,IN-VITRO,LANREOTIDE,EFFICACY,PROLIFERATION,GLUCAGONOMA,INHIBITION,MANAGEMENT},
  language     = {eng},
  number       = {1},
  pages        = {54--58},
  title        = {The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.},
  volume       = {72},
  year         = {2009},
}

Chicago
Verslype, C, S Carton, I Borbath, T Delaunoit, P Demetter, G Demolin, A Hendlisz, et al. 2009. “The Antiproliferative Effect of Somatostatin Analogs: Clinical Relevance in Patients with Neuroendocrine Gastro-entero-pancreatic Tumours.” Acta Gastro-enterologica Belgica 72 (1): 54–58.
APA
Verslype, C, Carton, S., Borbath, I., Delaunoit, T., Demetter, P., Demolin, G., Hendlisz, A., et al. (2009). The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. ACTA GASTRO-ENTEROLOGICA BELGICA, 72(1), 54–58.
Vancouver
1.
Verslype C, Carton S, Borbath I, Delaunoit T, Demetter P, Demolin G, et al. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. ACTA GASTRO-ENTEROLOGICA BELGICA. 2009;72(1):54–8.
MLA
Verslype, C, S Carton, I Borbath, et al. “The Antiproliferative Effect of Somatostatin Analogs: Clinical Relevance in Patients with Neuroendocrine Gastro-entero-pancreatic Tumours.” ACTA GASTRO-ENTEROLOGICA BELGICA 72.1 (2009): 54–58. Print.